Page last updated: 2024-12-07

sk&f 85174

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

SK&F 85174: dopamine receptor agonist; RN given refers to parent cpd; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID132435
CHEMBL ID130795
CHEMBL ID368456
SCHEMBL ID11273914
MeSH IDM0133426

Synonyms (14)

Synonym
77386-12-0
3-allyl-6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-1h-3-benzazepine-7,8-diol methanesulfonate
sk&f 85174-j
skf 85174
sk&f 85174
CHEMBL130795 ,
1h-3-benzazepine-7,8-diol, 6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-3-(2-propenyl)-
CHEMBL368456
3-allyl-6-chloro-1-(4-hydroxy-phenyl)-2,3,4,5-tetrahydro-1h-benzo[d]azepine-7,8-diol
bdbm50019389
SCHEMBL11273914
3-allyl-6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-1h-3-benzazepine-7,8-diol
DTXSID50998600
6-chloro-1-(4-hydroxyphenyl)-3-(prop-2-en-1-yl)-2,3,4,5-tetrahydro-1h-3-benzazepine-7,8-diol
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID59807Tested in vivo for change in maximal arterial pressure (MAP)in dog after intravenous dose of 30 mg/kg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
4-(Aminoalkyl)-7-hydroxy-2(3H)-indolones, a novel class of potent presynaptic dopamine receptor agonists.
AID59801Tested in vivo for change in maximal arterial pressure (MAP) in dog after intravenous dose of 3 mg/kg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
4-(Aminoalkyl)-7-hydroxy-2(3H)-indolones, a novel class of potent presynaptic dopamine receptor agonists.
AID59792Tested in vivo for change in heart rate (HR) in dog after intravenous dose of 3 mg/kg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
4-(Aminoalkyl)-7-hydroxy-2(3H)-indolones, a novel class of potent presynaptic dopamine receptor agonists.
AID59800Tested in vivo for change in maximal arterial pressure (MAP) in dog after intravenous dose of 0.3 mg/kg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
4-(Aminoalkyl)-7-hydroxy-2(3H)-indolones, a novel class of potent presynaptic dopamine receptor agonists.
AID59794Tested in vivo for change in heart rate (HR) in dog after intravenous dose of 30 mg/kg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
4-(Aminoalkyl)-7-hydroxy-2(3H)-indolones, a novel class of potent presynaptic dopamine receptor agonists.
AID59798Tested in vivo for change in heart rate in dog after intravenous dose of 0.3 mg/kg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
4-(Aminoalkyl)-7-hydroxy-2(3H)-indolones, a novel class of potent presynaptic dopamine receptor agonists.
AID62578Tested in vitro for dopamine agonist activity in rabbit ear artery after at a dose of 0.3 mg/kg1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
4-(Aminoalkyl)-7-hydroxy-2(3H)-indolones, a novel class of potent presynaptic dopamine receptor agonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (85.71)18.7374
1990's1 (14.29)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.99

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.99 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.29 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.99)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]